Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis
Y Zheng, Y Han, J Chen, J Huang, C Zhu, L Lin… - Indian Journal of …, 2024 - ijdvl.com
Background Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitors are novel treatments for
moderate-to-severe plaque psoriasis. Objective To perform a network meta-analysis to …
moderate-to-severe plaque psoriasis. Objective To perform a network meta-analysis to …
Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
T Hagino, H Saeki, E Fujimoto… - Journal of Dermatological …, 2024 - Taylor & Francis
Background Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor recently
approved for psoriasis. Objectives We aimed to evaluate the real-world effectiveness and …
approved for psoriasis. Objectives We aimed to evaluate the real-world effectiveness and …
Janus Kinases and Autoimmunity: Bridging Pathways to Therapy
Y Wei, T Zhang - International Journal of Drug Discovery and …, 2024 - sciltp.com
Janus kinase (JAK) is a family of intracellular non-receptor tyrosine kinases with four
members (JAK1, JAK2, JAK3, and Tyk2). The JAK-STAT (signal transducer and activator of …
members (JAK1, JAK2, JAK3, and Tyk2). The JAK-STAT (signal transducer and activator of …